Eli Lilly's anti-obesity drug retatrutide, showing up to 30% weight loss in trials, is not yet approved but is being sold online, raising safety concerns.
Unapproved drug sold online
Injectable pens containing Eli Lilly's anti-obesity drug retatrutide are being sold online despite the drug not being approved for market in the United States or Europe. These products are sometimes priced at several hundred euros and are not subject to the same safety and efficacy standards as approved medications.Drug targets multiple hormones
Retatrutide works by targeting three hormonal mechanisms—GLP-1, GIP, and glucagon—which are involved in regulating appetite and energy metabolism. This makes it distinct from other obesity treatments that typically target only one or two of these pathways.Clinical trial results show significant weight loss
In the TRIUMPH 1 trial, which included 2,339 adults with obesity or overweight, the 12 mg dose of retatrutide led to an average weight loss of 28.3% over 80 weeks. These results were achieved under controlled conditions with defined dosages and medical supervision.Regulatory status remains pending
As of October 19, 2026, retatrutide has not received market authorization in the United States or Europe. The drugmaker plans to submit an application to the American drug authority in the first quarter of 2027, pending further data and regulatory review.
